CELZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026

$0.72−0.02 (-2.35%)

Close on Oct 19, 2026

Market cap: $2.68M
P/E (TTM): –
Dividend yield: –

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31
Depreciation & Amortization	–	0.06	0.06	–	–	–	–	–	–	–	–	–	–	–	–	–
Stock-Based Compensation	0.00	0.04	0.04	0.07	0.60	0.10	0	0.00	0.14	0.00	–	–	–	–	–	–
Deferred Income Taxes	–	–	–	–	–	–	–	–	–	–	0	0	0	0	0	0
Other Non-Cash Items	–	–	–	–	–	–	–	–	–	–	–	–	–	-0.01	0.00	–
Change in Accounts Receivable	–	–	0	0.00	0.00	-0.01	0.00	0.00	0.00	0	–	–	–	–	–	–
Change in Inventory	0.00	0.00	0.00	0.00	-0.01	0	–	–	–	–	–	–	–	–	–	–
Change in Accounts Payable	0.00	-0.04	-2.95	2.51	0.41	0.03	-0.01	0.09	0.17	0.02	0.01	0.00	0.00	0.00	0.01	0.00
Operating Cash Flow	-5.86	-5.30	-8.03	-7.80	-2.22	-0.43	-1.21	-1.05	-0.89	-0.45	-0.01	-0.02	-0.02	-0.02	-0.01	-0.01
Acquisitions	–	–	–	–	0	-0.25	–	–	–	–	–	–	–	–	–	–
Purchase of Investments	–	0	-23	-10	–	–	–	–	–	–	–	–	–	–	–	–
Sale & Maturity of Investments	0	6.52	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Investing Cash Flow	-0.05	6.32	3.45	-10	0	-0.25	0	–	0	-0.01	0	0	0	0	0	0
Share Repurchases	-0.01	-0.17	-0.27	0	–	–	–	–	–	–	–	–	–	–	–	–
Stock Issued	7.17	1.63	0	15	15	0	–	0	0.10	0.50	–	–	–	–	–	–
Financing Cash Flow	7.17	1.45	-0.27	15	13	0.69	1.00	1.34	0.68	0.68	0.01	0.02	0.02	0.02	0.01	0.01
Net Change in Cash	1.27	2.47	–	–	–	0.01	-0.22	0.29	-0.21	0.22	0.00	0.00	0.00	0.00	0.00	0.00
Income Taxes Paid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Interest Paid	0	0	0	0	0.01	0.01	0.02	0.01	0.01	0	0.00	0	0.00	0	0	0

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 66.9%
Operating margin: -208004.4%
Net margin: -201355.4%
Return on equity, FY2025: -86.5%

Financial strength

Current ratio: 12.91
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 1247.4%

Valuation

P/E ratio: –
Price to sales: 892.84
Price to book: 0.31
Dividend yield: –